ReviewAmerican journal of translational research2025
Clinical effect of donepezil hydrochloride in the treatment of Parkinson's disease patients: a meta-analysis.
Review in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the therapeutic effectiveness of donepezil hydrochloride in patients with Parkinson's disease (PD) and inform subsequent management strategies.
methodsWe systematically reviewed randomized and non-randomized studies on donepezil hydrochloride in PD patients, retrieved from PubMed, Web of Science, Embase, and the Cochrane Library, covering data from inception to March 2025. Meta-analysis was performed using RevMan 5.4 software.
resultsTen eligible studies were included. The meta-analysis revealed significant improvements in Mini-Mental State Examination (MMSE) scores in the treatment group compared to controls (SMD = 1.67, 95% CI [0.81, 2.54], P < 0.0001). The Unified Parkinson's Disease Rating Scale (UPDRS) scores were significantly reduced (SMD = -2.79, 95% CI: -4.85 to -0.74, P = 0.008), as were Clinician's Interview-Based Impression of Change (CIBIC+) scores (SMD = -0.27, 95% CI: -0.45 to -0.08, P = 0.004). Subgroup analysis indicated consistent improvements in MMSE scores across different subgroups, with significant differences observed. Heterogeneity was found in the age subgroup but not in the disease duration subgroup (< 3 years). Adverse events occurred in 42.07% (374/889) of the treatment group, with no heterogeneity across studies (I
conclusionThe meta-analysis suggests that donepezil hydrochloride provides cognitive benefits for PD patients. However, the higher incidence of adverse reactions warrants careful consideration of the benefits and risks when using donepezil in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.